Status:
UNKNOWN
Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation
Lead Sponsor:
Chinese PLA General Hospital
Conditions:
Neoplasms, Therapy-Associated
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
This is a randomized ,opened, prospective controlled trial of clinical effectiveness for Icotinib as the adjunctive treatment after surgery in stage I-IIIB lung adenocarcinoma patients with epidermal ...
Detailed Description
In this trial the investigators will enlist 100 patients who accepted surgery and with epidermal growth factor receptor gene mutation,these patients will be divided into 2 groups (chemotherapy group a...
Eligibility Criteria
Inclusion
- 18-75 years old
- Lung adenocarcinoma patients with epidermal growth factor receptor gene mutation,stage I-IIIB after surgery
- The patients' Eastern Cooperative Oncology Group scores are ≤ 0-2
Exclusion
- Mismatch conditions above
- Have used other anti-cancer therapy drug before the trial and may influence the outcome
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2017
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT02283424
Start Date
October 1 2014
End Date
December 1 2017
Last Update
November 5 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
PLA General Hospital
Beijing, China, 100853